Milestone Pharmaceuticals (MIST) News Today $1.49 +0.01 (+0.68%) (As of 09:27 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Milestone Pharmaceuticals (MIST) Receives a Buy from TD CowenOctober 21, 2024 | markets.businessinsider.comMilestone Pharmaceuticals' (MIST) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Monday.October 14, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comIndividual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%October 9, 2024 | finance.yahoo.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Grows By 17.6%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 450,000 shares, a growth of 17.6% from the August 31st total of 382,600 shares. Based on an average trading volume of 116,500 shares, the short-interest ratio is presently 3.9 days.September 30, 2024 | marketbeat.comMIST Milestone Pharmaceuticals Inc.September 28, 2024 | seekingalpha.comMilestone Pharmaceuticals to Host Investor KOL EventSeptember 24, 2024 | markets.businessinsider.comIntroducing Mighty Mist™ by DayBreak Skincare, a Premium Hypochlorous Acid Mist for All Skin TypesSeptember 17, 2024 | reuters.comMilestone Says Ji Xing Reported Positive Topline Late-stage Study Results For Etripamil In PSVTSeptember 7, 2024 | markets.businessinsider.comMilestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in ChinaSeptember 6, 2024 | globenewswire.comMilestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of DirectorsSeptember 4, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024August 26, 2024 | finance.yahoo.comHC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report released on Thursday, August 22nd. HC Wainwright analyst P. Trucchio now forecasts that theAugust 26, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy RecommendationAugust 23, 2024 | msn.comMilestone Pharmaceuticals: A Buy Rating on CARDAMYST’s Market Potential and FDA ProgressAugust 22, 2024 | markets.businessinsider.comMilestone wins Buy at Rodman & Renshaw on potential Cardamyst approvalAugust 22, 2024 | msn.comHC Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST)HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Thursday.August 22, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & RenshawRodman & Renshaw started coverage on shares of Milestone Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $9.00 price objective on the stock.August 22, 2024 | marketbeat.comBuy Rating Affirmed for Milestone Pharmaceuticals on Etripamil’s Market Potential and Solid Financial FootingAugust 13, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateAugust 8, 2024 | globenewswire.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | 247wallst.comMilestone Pharmaceuticals Inc (MIST)July 31, 2024 | investing.comMilestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology ConferenceJuly 31, 2024 | finance.yahoo.comMilestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024June 12, 2024 | globenewswire.comQ1 2025 Earnings Estimate for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Issued By HC WainwrightMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Thursday, May 30th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.15) per shJune 3, 2024 | marketbeat.comMilestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 31, 2024 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Thursday.May 30, 2024 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYSTMay 29, 2024 | finanznachrichten.deMilestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™May 29, 2024 | globenewswire.comMilestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessMay 22, 2024 | finance.yahoo.comMilestone Pharmaceuticals Upgraded to Buy: Here's What You Should KnowMay 16, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ Strong Buy Rating: CARDAMYST’s FDA Resubmission and Bright Revenue ProspectsMay 16, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST)HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Thursday.May 16, 2024 | marketbeat.comMilestone Pharmaceuticals Inc MISTMay 14, 2024 | morningstar.comMilestone Pharmaceuticals: Q1 Earnings SnapshotMay 13, 2024 | washingtonpost.comMilestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateMay 13, 2024 | globenewswire.comMilestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024May 2, 2024 | finance.yahoo.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Decreases By 22.9%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 431,400 shares, a decline of 22.9% from the March 31st total of 559,500 shares. Based on an average daily volume of 312,600 shares, the short-interest ratio is currently 1.4 days.April 28, 2024 | marketbeat.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 17, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 17, 2024 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8%Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8%April 13, 2024 | marketbeat.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 8, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 8, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceApril 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual ConferencesApril 1, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular TachycardiaMarch 28, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)March 22, 2024 | markets.businessinsider.comMilestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Friday.March 22, 2024 | marketbeat.comMilestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy RecommendationMarch 21, 2024 | markets.businessinsider.com Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address 2 sentences that change everything you THOUGHT you knew about trading (Ad)If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running. Click here. MIST Media Mentions By Week MIST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼0.000.45▲Average Medical News Sentiment MIST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼01▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VERU News SLGL News DSGN News ACIU News STRO News INZY News URGN News AVIR News PRQR News GNFT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
